Increased sensitivity of lymphocytes from patients with systemic autoimmune diseases to DNA alkylation by the methylating carcinogen *N*-methyl-*N*-nitrosourea

P D LAWLEY,¹ R TOPPER,² A M DENMAN,² W HYLTON,² I D HILL,² AND G HARRIS³

From the ¹Institute of Cancer Research, Royal Cancer Hospital, Chester Beatty Laboratories, London; the ²Clinical Research Centre, Northwick Park Hospital, Harrow, Middlesex; and the ³Kennedy Institute of Rheumatology, London

SUMMARY Lymphocytes from patients with various diseases associated with autoimmunity showed both impaired capacity to repair *O*⁶-methylguanine (a powerful, promutagenic, directly miscoding base lesion) and increased sensitivity to the cytotoxic effects of cellular methylation by *N*-methyl-*N*-nitrosourea (MNU) compared with normal controls and patients with other disorders. Defective repair of *O*⁶-methylguanine was significantly associated with arthritis and myositis in the group with systemic lupus erythematosus (SLE), and increased sensitivity to the toxic action of MNU was associated with the presence of immune complexes and the administration of steroids to patients with Behçet's syndrome. The results indicate that lymphocytes from patients with the autoimmune diseases studied are more susceptible to DNA damage with possible relevance to aetiopathogenesis.

Key words: DNA repair, mutation, rheumatoid arthritis, SLE.

Autoimmune diseases have a multifactorial pathogenesis with a genetic basis. The potent carcinogenic agent *N*-methyl-*N*-nitrosourea (MNU) alkylates DNA to form a powerful promutagenic base lesion, *O*⁶-methylguanine (*O*⁶-MeGua), which has been found to induce the development of autoimmunity in susceptible strains of inbred mice, haemolytic anaemia and T cell malignancies being the main clinical features.¹ Murine lymphocytes are severely defective in the repair of *O*⁶-MeGua while lymphocytes from healthy human donors are relatively proficient.² This repair activity has been studied in cells from patients with autoimmune diseases and they also showed evidence of defective DNA repair.³

This paper assesses DNA repair in a larger population of people with autoimmune diseases and examines the results in relation to the clinical features of the diseases.

Patients and methods

PATIENTS

A total of 245 individuals were studied in the following categories:

- (a) Systemic lupus erythematosus (SLE). Forty eight patients satisfying Arthritis and Rheumatism Association criteria.⁴ Disease duration was four months to 38 years (mean 8.2 years).
- (b) Rheumatoid arthritis (RA). Twenty one patients satisfying the diagnostic criteria of Ropes *et al.*⁵ Disease duration was two months to 20 years (mean 6.4 years).
- (c) Behçet's syndrome. Fifty three patients with established diagnostic features.⁶ Disease duration was nine months to 36 years (mean 10.6 years).
- (d) Scleroderma. Thirteen patients who fulfilled the diagnostic criteria of Masi *et al.*⁷ Disease duration was six months to 17 years (mean 10.0 years).
- (e) Miscellaneous autoimmune diseases. Thirty eight patients, including cases of myositis, polyarteritis nodosa, Sjögren's syndrome, and unclassified

Accepted for publication 16 December 1987.
Correspondence to Dr A M Denman, Clinical Research Centre, Northwick Park Hospital, Harrow, Middlesex HA1 3UJ.

polyarthritis. Disease duration was one month to 11 years (mean 2.9 years).

(f) Hospital controls. Fifty three patients with miscellaneous non-autoimmune conditions such as pneumonia, myocardial infarction, carcinomas of lung, colon, etc were studied. Disease duration was one month to 42 years (mean 6.5 years).

(g) Healthy controls. Twenty three healthy laboratory staff were used (aged 21–56, mean 34 years). Blood samples were obtained with approval of the ethical committee of Northwick Park Hospital.

TOXICITY STUDIES

Human mononuclear cells were obtained from peripheral blood by density gradient separation. For toxicity studies lymphocytes were cultured in 3 ml volumes (0.5×10^6 cells/ml) in RPMI 1640 medium supplemented with 5% fetal calf serum and 0.05 mM 2-mercaptoethanol in flat bottomed 'Linbro' tissue culture plates. Concanavalin A (con A) was added (Sigma; 4 µg/ml) at the start of the culture period. Cell counts were made on day 7, the time of maximal increase in cell numbers. MNU was added at the beginning of culture in varying concentrations and was not removed in view of its short half life of <15 minutes. Results are the means of triplicate cultures. The assessment of toxicity was carried out on coded samples.

CHEMICAL METHODS

The carcinogen, MNU, was prepared by nitrosation of its methylurea and used as described in detail previously.¹ In principle, cells suspended in isotonic saline (pH 6.4) at a concentration of $5\text{--}10 \times 10^6$ cells/ml were exposed to $N\text{--}[^{14}\text{C}]\text{methyl-}N\text{--nitroso-urea}$ ($[^{14}\text{C}]\text{MNU}$) (Amersham International plc, Amersham, Bucks), specific activity 2.26 GBq/mmol. As removal of $O^6\text{-MeGua}$ is rapid in proficient cells the period of exposure was one hour.⁸ DNA was extracted and chromatographed as previously described using high performance liquid chromatography.⁸ The radioactivity in one minute fractions, indicated by the ultraviolet (UV) absorption of added marker methylpurines, was determined by liquid scintillation counting. The amount of DNA was determined from the UV absorption of guanine (ϵ max 11 400) and adenine (ϵ max 13 100), and the amounts of methylpurines after exposure to $[^{14}\text{C}]\text{MNU}$ were thus determined and expressed as µmol/mol DNA-P. The ratio of $O^6\text{-MeGua}$ to 7-MeGua in DNA was taken as an indicator of proficiency of removing $O^6\text{-MeGua}$ from methylated cellular DNA as the removal of 7-MeGua is slow even in normal lymphocytes.^{2,3}

STATISTICAL METHODS

In seeking any altered susceptibility of lymphocytes

from patients with autoimmune disease to inhibition of growth by MNU the following points were assessed: (a) replicate assays on the same sample; (b) variations between sequential samples from the same donor; and (c) differences between patients and control groups, taking into account both diagnostic and disease features.

Equivalent normal deviates (ENDs) were calculated, as (patient value—control mean)/control SD, to determine which curves of inhibition of growth by MNU were significantly abnormal. In this way results were obtained which were observations from a distribution with mean 0.0 and SD 1.0 if there were no differences between patients and controls. Comparison of the results with tables of the standard normal curve therefore gives a probability that is comparable across all observations.

The computer program 'GLIM' was used to analyse any differences between donor groups in the growth of con A stimulated lymphocytes unexposed to MNU. This response to con A was examined in relation to age and sex of the patients and controls.

The ratio ($O^6\text{-MeGua}$)/(7-MeGua), used as an index of repair of $O^6\text{-MeGua}$ by treated lymphocytes,⁸ was analysed by Student's *t* test. The ratios were examined in relation to clinical features by stepwise multiple regression using the computer program 'Minitab'.

Any missing values were replaced by random values taken from the distribution of recorded values. To assess the effect of this technique each run was performed five times using different random numbers, and no substantial changes were found as a result.

Results

TOXICITY

Lymphocytes from all donors proliferated in response to con A, more than doubling in number during seven days of culture, and this response was not significantly affected by age, sex, or disease. The ability of cultured human lymphocytes to divide in response to con A after initial damage by MNU was impaired in patients with autoimmune disease compared with healthy donors or patients without evidence of autoimmune disease (Fig. 1). The results were calculated as percentages of the growth of control cultures not exposed to MNU as previously described.²

The in vitro sensitivity of lymphocytes from these patients to varying concentrations of MNU was studied taking into account their clinical status and the results of their laboratory investigations. For this purpose for each patient the inhibition of growth at each concentration of MNU was compared with the

mean and standard deviation of the percentage inhibition of growth of the healthy control group. Up to five results corresponding to the concentrations of MNU added to the cultures were used for each patient and from these results the equivalent

Fig. 1 The inhibitory effect of varying concentrations of *N*-methyl-*N*-nitrosourea (MNU) on the growth of human lymphocytes in response to con A, expressed as percentage of the growth of untreated cultures. The mean growth curve for each disease group is shown. The shaded area represents the 95% confidence limits for the healthy controls.

Table 1 Range of equivalent normal deviates (ENDs) for inhibition of lymphocyte growth by *N*-methyl-*N*-nitrosourea

Group	ENDs
SLE	1.60 to -17.79
RA	1.96 to -7.54
Behçet's	0.74 to -9.57
Scleroderma	1.95 to -6.55
Miscellaneous autoimmune diseases	1.27 to -8.00
Hospital controls	1.87 to -9.59
Healthy controls	1.87 to -6.95

The ENDs were calculated as indicated in the text.

Table 2 The range of equivalent normal deviates (ENDs) for toxicity of *N*-methyl-*N*-nitrosourea to lymphocytes from patients with autoimmune diseases

Disease	Group I (1.96 to -1.17)	Group II (-1.17 to -3.79)	Group III (-3.79 to -17.79)
SLE	17	14	17
RA	7	8	6
Behçet's	13	17	23
Scleroderma	8	4	1
Miscellaneous autoimmune	16	13	9

The ENDs were calculated and the results were grouped as indicated in the text.

normal deviate (END) for each patient was calculated (Table 1).

Fig. 2 shows the range of END values for healthy controls and for patients with Behçet's syndrome. Most of the healthy controls had ENDs between 2 and -1 as compared with only 15% of the donors with Behçet's syndrome. Similar distributions (not shown) were found for the other autoimmune groups.

The ENDs from all the autoimmune disease groups were taken together and put into numerical order and divided into three equal groups, to allow comparison between groups I and III (Table 2). The results in patients with autoimmune disease showed a wide range of values, but significant numbers showed increased cellular sensitivity to the toxic action of MNU (Table 2).

Clinical features and laboratory results were analysed in relation to these toxicity studies (Table 3). Increased sensitivity of blood lymphocytes to

Fig. 2 Histograms showing the distribution of ENDs for (A) the healthy controls and (B) the group of patients with Behçet's syndrome.

MNU was associated with circulating immune complexes and treatment with steroids. Conversely, significantly more patients who had shown low levels of serum IgG (<8.9 g/l) during the course of their disease were found to be in group I (i.e., the group most nearly resembling the controls) rather than group III.

DNA REPAIR STUDIES

Fig. 3 shows the products of methylation of blood lymphocyte DNA with [^{14}C]MNU in the chromatogram from a patient with SLE one hour after initial exposure. There was deficiency of O^6 -MeGua repaired while 3-methyladenine was proficiently removed. The removal of 7-MeGua was slow and there was no

Table 3 Summary of sensitivity to *N*-methyl-*N*-nitrosourea (MNU) in relation to clinical features and laboratory results

Disease	Summary of sensitivity	Group I	Group III
SLE	More patients with alopecia were in group III ($p=0.057$)	3/15*	7/12
	Significantly more patients in group I than group III showed altered levels of serum immunoglobulins ($p=0.0043$)	12/14	3/12
	This was also true for IgA ($p=0.081$)	6/14	1/12
RA	More patients with vasculitis were found in group III than in group I ($p=0.045$)	0/7	3/5
Behçet's	A higher proportion of patients in group III were taking steroids than in group I ($p=0.082$)	3/20	8/19
Scleroderma	Older patients (>40 years) were found in group I (only 14 patients were studied) ($p=0.048$)	4/5	0/4
Miscellaneous autoimmune	Significantly more patients with circulating immune complexes at some point in their illness were found in group III than in group I ($p=0.050$)	1/8	6/9

*Figures are (number with stated feature)/(number in each group).

No relation was found between MNU sensitivity and (a) presence or severity of arthritis, cardiovascular, pulmonary, skin, renal, gastrointestinal, or central nervous system features; (b) disease duration; (c) treatment with non-steroidal anti-inflammatory drugs, gold, or penicillamine (RA) or cytotoxic drugs (all diseases); and (d) haemoglobin, white cell count, erythrocyte sedimentation rate, immunoglobulin concentration, complement levels, immune complexes, and autoantibodies.

Table 4 Repair of O^6 -methylguanine (O^6 -MeGua) in human lymphocytes

Disease	n	O^6 -MeGua/7-MeGua		t Value	Degrees of freedom	Probability
		Mean	SD			
SLE	29	0.068	0.012	-2.41	44	0.020
RA	15	0.070	0.010	-3.20	30	0.003
Behçet's	17	0.069	0.012	-2.77	45	0.008
Scleroderma	5	0.058	0.006	0.51	20	0.616
Miscellaneous autoimmune	18	0.069	0.010	-2.86	33	0.007
Hospital controls	17	0.063	0.010	-0.94	32	0.354
Healthy controls	17	0.060	0.008	—	—	—

The means and standard deviations for each group of the ratio (O^6 -MeGua)/(7-MeGua) in lymphocytes obtained from the peripheral blood one hour after initial exposure to 0.1 mM [^{14}C]MNU are shown. The *t* tests done between the healthy control group and each patient group are also tabulated.

significant removal in the first 24 hours after exposure to MNU. Proficient cells would be expected to remove around 50% of O^6 -MeGua from their DNA during the first hour after initial expo-

sure to [14 C]MNU giving a ratio of O^6 -MeGua to 7-MeGua of 0.055. In the example shown in Fig. 3 this value was 0.088.

Control donors had generally lower ratios than the other groups, indicating more proficient repair of O^6 -MeGua (Fig. 4). Significant differences were found between the healthy control group and donors with Behçet's syndrome, SLE, RA, and the group of miscellaneous autoimmune diseases but not scleroderma (Table 4).

When repair proficiency of O^6 -MeGua was analysed in terms of specific clinical and laboratory findings arthritis in the group with SLE, myositis in the group with miscellaneous autoimmune diseases, and disease activity in the group with RA were significantly associated with reduced O^6 -MeGua repair (Table 5).

Fig. 3 A typical chromatogram showing the methylation products found in DNA isolated from deficient lymphocytes from a patient with SLE treated in vitro one hour previously with N-methyl-N-nitrosourea (MNU). Extent of MNU methylation of lymphocyte DNA μ mol/mol phosphorus is shown in brackets.

Fig. 4 Ratios of (O^6 -MeGua)/(7-MeGua) in DNA of human lymphocytes isolated one hour after the addition of [14 C]MNU.

Table 5 Summary of significant defects in repair of O^6 -methylguanine, as indicated by (O^6 -MeGua)/(7-MeGua), in relation to clinical features and laboratory results

Disease	Relation to clinical features	t Value (degrees of freedom)	Probability
SLE	There appeared to be a significant positive relation with arthritis	2.16 (26)	0.05
RA	A significant negative relation with disease activity	-3.53 (14)	0.003
Behçet's	Nil		
Scleroderma	Nil		
Miscellaneous autoimmune	A significant positive relation with myositis	2.8 (25)	0.05
Hospital controls	Nil		

No correlation with disease features listed in footnote to Table 3.

Discussion

These results extend preliminary observations indicating that autoimmune diseases may be associated with at least one form of impaired DNA repair proficiency.³ In addition to establishing this association in several such disorders, increased sensitivity to MNU could be correlated with specific disease features. The association between steroid treatment in Behçet's syndrome and increased susceptibility may reflect disease severity rather than a direct effect of steroid treatment on lymphocytes as a similar association was not found in other autoimmune diseases.

The concept of somatic mutation as a basis for autoimmune disease is an extension of the clonal selection hypothesis of antibody formation.⁹ It is now established that somatic DNA recombination¹⁰ and point mutations¹¹ are involved in physiological B cell differentiation and expression of immunoglobulin genes. Although somatic mutation is important for normal antibody synthesis, however, a specific V gene mutation in a cell line has been found to give rise to antibody with autoantibody specificity.¹² Thus similar mutations could give rise to autoantibody production in human disease.

The formation in DNA of a potent promutagenic base lesion, *O*⁶-MeGua, is associated with the development of autoimmune haemolytic anaemia in susceptible strains of mice.¹ *O*⁶-MeGua in DNA is repaired by direct reversal with conversion back to guanine. The rate of repair of this lesion is important in determining the extent of mutation¹³ as cell division by unrepaired cells results in direct miscoding during DNA replication, thymidine instead of cytidine pairing with *O*⁶-MeGua. Furthermore, murine lymphocytes are deficient in removing *O*⁶-MeGua from DNA.² Thus it was logical to study the responses to MNU of lymphocytes from patients with autoimmune diseases as reduced repair proficiency and altered sensitivity may indicate increased susceptibility to potent environmental mutagens relevant to the pathogenesis of these disorders.

The results show that blood lymphocytes from patients with certain autoimmune diseases are relatively deficient in the repair of *O*⁶-MeGua and also show increased sensitivity to the toxic effects of MNU compared with normal subjects and patients with other disorders. There was considerable overlap and this reduced proficiency does not absolutely discriminate between patients with autoimmune diseases and other individuals. It may, however, identify a risk factor analogous with inherited complement deficiency.

It is unlikely that reduced repair proficiency

simply reflects the effects of non-specific factors such as inflammatory mediators or changes in circulating lymphocyte populations. Repair proficiency in inflammatory diseases not associated with autoimmunity was comparable with that in normal controls. T and non-T lymphocytes isolated from the same donor show identical repair proficiency.³ In addition, the repair proficiency of Epstein-Barr virus transformed lymphoblastoid cell lines reflects that of the blood lymphocytes from which such lines are obtained.⁸ Unequivocal DNA repair defects have been detailed in rare, usually inherited, disorders.¹⁴ Similar evidence is sparse in autoimmune diseases, though reduced repair proficiency of UV induced damage in skin fibroblast DNA has been claimed in SLE,^{15,16} albeit with conflicting results.¹⁷ Blood lymphocytes from patients with RA and SLE proved abnormally sensitive to α irradiation in vitro and were defective in repair of radiation induced DNA damage.¹⁸ It is noteworthy that concentrations of the relevant repair enzyme *O*⁶-alkylguanine-DNA alkyltransferase have been reported to be low in normal human myeloid cells and this has been considered a risk factor in leukaemogenesis.¹⁹

Proficient repair of *O*⁶-MeGua is not directly related to resistance to MNU toxicity as this mutagen induces several cytotoxic lesions. In particular 3-MeAde is an important lesion but all human lymphocytes so far studied are proficient in its repair.⁸ Thus although the present data indicate that lymphocytes from patients with autoimmune diseases show increased sensitivity to MNU and deficient repair of *O*⁶-MeGua, the two defects need not necessarily be related.

Cellular DNA repair defects of this kind could be genetically determined or result from external factors influencing cellular DNA repair, including virus infections.¹⁸ Failure to repair DNA damage efficiently may produce an increased rate of somatic mutations in target cells with resultant autoimmune disease.¹⁷ Family studies are needed to distinguish between genetic and acquired factors.

References

- Harris G, Lawley P D, Asberry L J, Chandler P M, Jones M G. Autoimmune haemolytic disease in mice after exposure to a methylating carcinogen. *Immunology* 1983; **49**: 439-49.
- Harris G, Lawley P D, Olsen I. Mode of action of methylating carcinogens: comparative studies of murine and human cells. *Carcinogenesis* 1981; **1**: 403-11.
- Harris G, Asberry L, Lawley P D, Denman A M, Hylton W. Defective repair of *O*⁶-methylguanine in autoimmune diseases. *Lancet* 1982; **ii**: 952-6.
- Tan E M, Cohen A S, Fries J F, *et al*. Revised criteria for the classification of SLE. *Arthritis Rheum* 1982; **25**: 1271-7.
- Ropes M W, Bennett G A, Cobb S, Jacox R, Jessar R A. Revision of diagnostic criteria for rheumatoid arthritis. *Bull Rheum Dis* 1958; **9**: 175-6.

- 6 Mason R M, Barnes C G. Behçet's syndrome with arthritis. *Ann Rheum Dis* 1969; **28**: 95–103.
- 7 Masi A T, Rodnan G P, Medsger T A. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980; **23**: 581–90.
- 8 Lawley P D, Harris G, Phillips E, *et al*. Repair of chemical carcinogen-induced damage in DNA of human lymphocytes and lymphoid cell line—studies of the kinetics of removal of *O*⁶-methylguanine and 3-methyladenine. *Chem Biol Interact* 1986; **57**: 107–21.
- 9 Burnet F. N. Intrinsic mutagenesis: a genetic basis of ageing. *Pathology* 1974; **6**: 1–11.
- 10 Tonegawa S. Somatic generation of antibody diversity. *Nature* 1983; **302**: 575–81.
- 11 Griffiths G M, Berek C, Kaartinen M, Milstein C. Somatic mutation and the maturation of the immune response to 2-phenyloxazolone. *Nature* 1984; **312**: 271–5.
- 12 Diamond B, Scharff M D. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. *Proc Natl Acad Sci USA* 1984; **81**: 5841–4.
- 13 Jeggo P. Isolation and characterisation of *E. coli* K12 mutants unable to induce the adaptive response to simple alkylating agents. *J Bacteriol* 1979; **139**: 783–91.
- 14 Friedberg E C, Ehmann U K, Williams J I. Human diseases associated with defective DNA repair. *Advances in Radiation Biology* 1979; **8**: 85–174.
- 15 Harris G. DNA damage and repair in immunologically active cells (II). *Immunol Today* 1983; **4**: 109–12.
- 16 Theofilopoulos A N, Prud'homme G J, Dixon F J. Auto-immune aspects of systemic lupus erythematosus. In: J M Cruse, R E Lewis, eds. *Current concepts in immunopathology*. Vol. 1. Basel, New York: Karger, 1985: 190–218.
- 17 Cleaver J E. DNA damage and repair in light sensitive human skin disease. *J Invest Dermatol* 1970; **54**: 181–95.
- 18 Harris G, Cramp W A, Edwards J C, *et al*. Radiosensitivity of peripheral blood lymphocytes in autoimmune disease. *Int J Radiat Biol* 1985; **47**: 689–99.
- 19 Genson S L, Miller K, Berter N A. *O*⁶-Alkylguanine-DNA alkyltransferase activity in human myeloid cells. *J Clin Invest* 1985; **76**: 2106–14.